The global cancer diagnostics market size was USD 18.2 billion in 2021 and it is estimated to reach USD 43.7 billion by 2031, growing at a rate of 9.2% from 2022-2031.
Get Access to A Free Sample Copy of Our Latest Report – https://www.globalinsightservices.com/request-sample/GIS10252
Cancer diagnostics is a method of identifying different diagnostics, proteins, and some signs that leads to the identification of the presence of a cancerous tumor. Efficient diagnostic testing is used to validate or rule out the existence of illness, monitor the progression of the disease, and schedule & review treatment outcomes. Diagnostic procedures for cancer may comprise imaging, tumor biopsy, laboratory tests (comprises tests for tumor diagnostics), endoscopic examination, surgery, or genetic testing.
Market Trends and Drivers
The key factor boosting the growth of the market is the growth in the number of private diagnostic centers. The number of private diagnostic centers is increasing across the world as there is a rising demand for diagnostic imaging procedures and a growing burden on public hospitals owing to the limited number of imaging modalities at their disposal.
Major Players in Global Cancer Diagnostics Market
The key players analyzed in the global cancer diagnostics market are GE Healthcare (US), Abbott Laboratories (US), Hologic Inc. (US), Agilent Technologies Inc.(US), Roche Diagnostics (Switzerland), FUJIFILM Corporation (Japan), Danaher Corporation (US), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (US), Siemens Healthineers AG (Germany), BD (US), bioMérieux SA (France), Bio-Rad Laboratories (US), Cancer Diagnostics Inc. (US), Vela Diagnostics (Singapore), Roche Diagnostics (Switzerland), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (US), Bio SB (US), Biocartis NV (Belgium), Exact Science (US).
COVID-19 Analysis
With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies and small startups has stepped forward to develop treatments and vaccines that target the infection caused by the COVID-19. The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide. This has been primarily managed by dramatically reducing inpatient and outpatient services for other diseases and implementing infection prevention and control measures. The number of cancer screening and diagnostic procedures declined precipitously, with countries worldwide being affected by the COVID-19 pandemic.
Market Segments
By Product
- Consumables
- Instruments
By Technology
- IVD Testing
- Imaging
- Biopsy Technique
By Application
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Other Cancers
Get A Customized Scope to Match Your Need Ask an Expert- https://www.globalinsightservices.com/request-customization/GIS10252
By End User
- Hospitals
- Diagnostic Laboratories
With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Excel data pack included with all report purchases
- Robust and transparent research methodology
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1–833–761–1700
Website: https://www.globalinsightservices.com/